VENTOLIN ROTACAPS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VENTOLIN ROTACAPS (VENTOLIN ROTACAPS).
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
| Metabolism | Metabolized primarily by sulfation in the gut wall and to a lesser extent by hepatic conjugation via monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT). |
| Excretion | Renal (60-70% as unchanged drug and metabolites, primarily as sulfate conjugate); biliary/fecal (minimal, <10%) |
| Half-life | Terminal elimination half-life: 3-6 hours in adults; prolonged in patients with renal impairment or hepatic dysfunction (up to 12 hours). Clinical context: Dosing interval typically every 4-6 hours. |
| Protein binding | Approximately 10% bound to plasma proteins (albumin and alpha-1-acid glycoprotein). |
| Volume of Distribution | Approximately 2-3 L/kg; indicates extensive distribution into tissues (e.g., lungs, skeletal muscle). |
| Bioavailability | Inhalation: 10-20% (varies with device and technique). Oral: 30-50% (first-pass metabolism produces sulfate conjugate; low systemic bioavailability). |
| Onset of Action | Inhalation: 5-15 minutes; peak effect at 30-60 minutes. Oral: 30-90 minutes. |
| Duration of Action | Inhalation: 4-6 hours (bronchodilation). Clinical note: Tolerance may develop with chronic use; duration may be shorter in acute severe asthma. |
| Molecular Weight | 239.31 |
Inhalation via Rotahaler: 200-400 mcg (1-2 capsules) every 4-6 hours as needed for bronchospasm; maximum 4 times daily.
| Dosage form | CAPSULE |
| Renal impairment | No dosage adjustment necessary for renal impairment. |
| Liver impairment | No dosage adjustment necessary for hepatic impairment. |
| Pediatric use | Children 4-11 years: 200 mcg (1 capsule) via Rotahaler every 4-6 hours as needed; maximum 4 times daily. Children over 12 years: same as adult. |
| Geriatric use | No specific dose adjustment; use lowest effective dose due to potential for increased sensitivity and tremor. Monitor cardiovascular effects. |
| 1st trimester | Limited human data; animal studies show no teratogenic effects. Use only if benefit outweighs risk. |
| 2nd trimester | Generally considered safe; may be used for bronchospasm. Monitor maternal heart rate and blood glucose. |
| 3rd trimester | May cause maternal tachycardia and fetal tachycardia; avoid near term due to potential for uterine relaxation and delay labor. |
Clinical note
Comprehensive clinical and safety monograph for VENTOLIN ROTACAPS (VENTOLIN ROTACAPS).
| Placental transfer | Salbutamol crosses the placenta; fetal cord blood concentrations are approximately 0.5-1 times maternal plasma levels after inhalation. |
| Breastfeeding | Salbutamol is excreted into breast milk in small amounts (estimated 0.3% of maternal dose). No adverse effects reported in infants. Use with caution in preterm infants due to potential for respiratory depression. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
Hypersensitivity to salbutamol or any componentTachyarrhythmias (e.g., ventricular tachycardia)Severe coronary artery disease (relative, risk of ischemia)
| Precautions | Paradoxical bronchospasm may occur, Cardiovascular effects: increases heart rate, blood pressure, Hypokalemia may occur, Risk of immediate hypersensitivity reactions, Do not use as substitute for inhaled or oral corticosteroids |
| Food/Dietary | None specific to salbutamol. However, avoid excessive caffeine (coffee, tea, cola) as it may increase the risk of nervousness, tremor, and palpitations. No dietary restrictions required. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate studies in pregnant women; animal studies show adverse effects at high doses. In first trimester, use only if benefit justifies risk. Second and third trimesters: risk of fetal tachycardia, hypoglycemia, and maternal pulmonary edema if used with beta-agonists. Avoid for tocolysis due to serious maternal adverse events (pulmonary edema, death). |
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, serum potassium (risk of hypokalemia), and respiratory status. Fetal monitoring for heart rate changes (tachycardia, arrhythmias) and signs of distress. Assess uterine activity if used for tocolysis. Monitor for signs of pulmonary edema if used with other beta-agonists. |
| Fertility Effects | No known adverse effects on fertility in humans. Animal studies show no impairment of fertility at therapeutic doses. |
| Clinical Pearls |
| Ventolin Rotacaps contain micronized salbutamol sulfate in a lactose carrier. They require a specific inhaler device (Rotahaler) for proper dose delivery. Rotacaps are for oral inhalation only, not for oral ingestion. The capsule should be pierced only by the Rotahaler; do not open or inhale intact capsules. Efficacy depends on correct placement in the Rotahaler and swift inhalation. Priming the device before first use is not necessary, but patients should be taught to load a new capsule for each dose. The dose-response curve is steep; doubling the dose may not produce additional bronchodilation but can increase adverse effects. |
| Patient Advice | Use one Rotacap per dose; insert into Rotahaler just before use. · Do not swallow the capsule; it is for inhalation only. · Twist the Rotahaler to break the capsule, then inhale deeply and rapidly. · Hold breath for 10 seconds after inhalation, then exhale slowly. · Rinse mouth with water after each use to prevent throat irritation and candidiasis. · Do not exceed prescribed number of doses per day; seek medical help if symptoms worsen. · Store Rotacaps in a dry place at room temperature; avoid moisture. · If a dose is missed, take it as soon as remembered unless it is almost time for the next dose; do not double the dose. · Inform your doctor if you have heart problems, high blood pressure, diabetes, or seizure disorders. · Seek emergency care if you experience chest pain, rapid heart rate, or worsening breathing. |